CSA/AZA, in the absence of prednisone, improves linear growth in renal transplanted children

Area of Science:

• Pediatric Nephrology
• Transplantation Immunology
• Immunosuppressive Therapy

Background:

• Renal transplantation is a vital treatment for pediatric end-stage renal disease.
• Optimizing immunosuppressive regimens is crucial for long-term graft survival and patient growth.
• Comparing calcineurin inhibitors with traditional immunosuppressants is essential for pediatric transplant outcomes.

Purpose of the Study:

• To compare the efficacy and safety of cyclosporine/azathioprine (CSA/AZA) versus prednisone-based immunosuppression in pediatric renal transplant recipients.
• To evaluate graft survival, renal function, lipid profiles, and growth parameters between the two treatment groups.

Main Methods:

• A retrospective comparison of 44 pediatric renal transplant recipients.
• Two groups: 24 treated with CSA/AZA, 20 with prednisone plus AZA and/or CSA.
• Follow-up included assessment of graft loss, serum creatinine, lipid profiles, and height standard deviation scores (SDS).

Main Results:

• The CSA/AZA group had significantly better graft survival (0% vs. 25% graft loss).
• CSA/AZA treatment led to improved height SDS over 36 months compared to prednisone.
• While both groups showed increased serum creatinine, the CSA/AZA group had better HDL and lower VLDL and triglyceride levels.

Conclusions:

• CSA/AZA is a favorable immunosuppressive regimen for initial pediatric renal transplants, promoting better growth and graft survival.
• Prednisone-based immunosuppression was associated with higher graft loss and poorer growth outcomes.
• Careful monitoring for potential adverse effects of CSA/AZA is warranted, as 25% of patients experienced graft damage.